Most Popular Stories
- Interview: Behind WellPoint's $1B primary care initiative
- Healthcare jobs will grow the fastest of all industries
- Hospitals criticized for patient data-mining
- Smartphone-powered monitoring to rise to 3 million users by 2016
- Young docs fuel palliative medicine, reveal generational differences
- Blues' Horizon invests $1M to train medical home care coordinators
Featured Jobs
-
Electronic Health Records Application Support Manager RN-New Year New Career
Avanti on behalf of Respected Health System - San Francisco, CA -
ICD-10 Revenue Cycle, Manager
Meditology Services - Atlanta, GA -
Epic Ambulatory Beacon Consultant
Meditology Services - NC
Events
- Medical Devices Summit 2012
March 6-7 2012 — The Boston Park Plaza Hotel & Towers, Boston, MA - ICD-10 Reality Check - Breakfast Panel at HiMSS 2012!
February 22, 2012 - Wharton Health Care Business Conference
Feb 16-17 — Philadelphia, PA - AHIP's Institute 2012
June 20-22 — Salt Lake City, UT
Paid Research Reports
- Electronic health records: getting it right first time
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Stakeholder Opinions: Ophthalmology - Leading brands under threat
- Genomics, Proteomics and Metabolomics in Diagnostics: Market landscape, innovative technologies and future outlook
- Healthcare Regulatory Update: The United Arab Emirates
- Point of Care Testing: Evaluating the return to evidence based medicine, novel technologies and the competitive landscape
Free Newsletter
FierceHealthcare is the leading source of healthcare management news for healthcare industry executives. Join 50,000+ healthcare industry insiders who get FierceHealthcare via daily email. Sign up today!
Popular Topics
Prominent political donor gets experimental drug without permission
A prominent political donor for the Democratic party has apparently gotten his hands on an experimental drug to fight cancer over the objections of the drugmaker.
The drug, Tysabri, which is manufactured by Biogen Idec Inc., is approved only for use in patients with multiple sclerosis or Crohn's disease. Biogen refused to give permission for it to be used in a single-patient investigation on the ailing donor, Fred Baron, in spite of pleas from many high-profile figures like former President Bill Clinton and cyclist Lance Armstrong. Nonetheless, Baron received the drug at the Mayo Clinic, which apparently managed to work out a "legal basis" to give him the drug in cooperation with the FDA.
This is the latest in a number of cases in which individuals have fought to get access to drugs outside of normal group trials. Sometimes it is seen as the last chance for an ailing patient, such as in this case, in which Baron had been told he likely only had days to live without treatment.
Pharmaceutical companies, on the other hand, are often concerned that allowing end-stage patients access to trials will skew the number of deaths that show up in the final numbers, and possibly prevent the drug from passing the FDA's requirements. Time will tell whether the pharmaceutical companies or the individual patients will get the upper hand in this tough battle.
To learn more about Baron's struggle:
- Read this Chicago Tribune piece
Related Articles:
Boy wins right to take experimental drug
Suit could open up experimental drug access
Suit challenges biotech firm over last-chance drug
Related Stories
- Boy wins right to take experimental drug
- Conflicts of interest remain as docs receive $760M from drug makers
- Colorado teaching hospitals overhaul conflict of interest rules
- Big drug companies wield too much influence over doctors
- Study: Attitudes over doctor-industry ties not as evolved as we think
- SPOTLIGHT: Relationships between docs, drug companies also a problem in India
- Price hikes could raise $10 billion in additional income for pharmas
- Reform bill would require pharma disclosures of CME funding
- Pharmas settle $124M Medicaid fraud suit; Legislators fight for 'critical access' funding for rural hospitals;
- CME accreditation body plans exposure of courses violating drugmaker influence rules
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site Map
| Editors | List in Marketplace | Supplier in MarketplaceTHE FIERCEMARKETS NETWORKFierceEnergy | FierceSmartGrid | FierceFinance | FierceFinanceIT | FierceComplianceIT | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare | FierceHealthPayer | FiercePracticeManagement | FierceEMR | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceGovernment | FierceHomelandSecurity | FierceBiotech | FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma Manufacturing | FierceMedicalDevices | FierceDrugDelivery | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceEnterpriseCommunications | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe | FierceCable© 2011 FierceMarkets. All rights reserved. |
![]() |
